Genentech Avastin Approved For Colorectal Cancer With Five-Month Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
The angiogenesis inhibitor gets full FDA approval Feb. 26. Genentech said it will begin shipping the biologic within three days.
You may also be interested in...
Roche Submits sNDA For New Chemotherapy Regimen In Metastatic Colorectal Cancer
Application is for Xelox (Xeloda plus oxaliplatin) with or without Genentech’s Avastin.
Roche Submits sNDA For New Chemotherapy Regimen In Metastatic Colorectal Cancer
Application is for Xelox (Xeloda plus oxaliplatin) with or without Genentech’s Avastin.
Genentech Pricing Strategy Is “Good For Society,” CEO Says
Levinson defends the high cost of targeted cancer treatments while suggesting the price of Avastin will increase.